Table 7 The BP-enriched KEGG pathways involving protein targets of at least nine antihypertensive drugs
BP-enriched KEGG pathway | Number of Antihypertensive drugs targeting pathway proteins | Number of Antihypertensive BP-protein targets |
|---|---|---|
hsa04924 Renin secretion | 45 | 9 |
hsa04022 cGMP-PKG signaling pathway | 39 | 10 |
hsa04020 Calcium signaling pathway | 32 | 10 |
hsa04024 cAMP signaling pathway | 30 | 9 |
hsa04261 Adrenergic signaling in cardiomyocytes | 29 | 8 |
hsa04270 Vascular smooth muscle contraction | 25 | 6 |
hsa05410 Hypertrophic cardiomyopathy (HCM) | 24 | 5 |
hsa01100 Metabolic pathways | 23 | 7 |
hsa05414 Dilated cardiomyopathy (DCM) | 21 | 5 |
hsa05142 Chagas disease (American trypanosomiasis) | 16 | 2 |
hsa04911 Insulin secretion | 13 | 6 |
hsa04540 Gap junction | 12 | 1 |
hsa04921 Oxytocin signaling pathway | 12 | 6 |
hsa04925 Aldosterone synthesis and secretion | 12 | 4 |
hsa04010 MAPK signaling pathway | 10 | 5 |
hsa04725 Cholinergic synapse | 10 | 5 |
hsa04728 Dopaminergic synapse | 10 | 3 |
hsa04912 GnRH signaling pathway | 10 | 3 |
hsa04713 Circadian entrainment | 9 | 2 |
hsa04720 Long-term potentiation | 9 | 1 |
hsa05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 9 | 4 |